This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Markers			
Low ERBB receptor feedback inhibitor 1 (ERRFI1; MIG6) to microRNA-200 (miR-200) ratio predicts response of cancers with wild-type epidermal growth factor receptor (EGFR) to EGFR inhibition	<p><i>In vitro</i> and mouse studies suggest a low MIG6 to miR-200 ratio could help predict response of tumors to EGFR inhibitors. In multiple cancer cell lines expressing wild-type EGFR, resistance to the EGFR inhibitor Tarceva erlotinib was associated with transforming growth factor-β1 (TGFB1)-induced epithelial-to-mesenchymal transition and MIG6 expression. In mice with human wild-type EGFR lung and pancreatic tumor xenografts, a high ratio of MIG6 to miR-200 was associated with resistance to erlotinib. Next steps could include validating the marker in additional patient samples.</p> <p>Astellas Pharma Inc., Chugai Pharmaceutical Co. Ltd. and the Genentech Inc. unit of Roche market Tarceva erlotinib to treat various cancers including non-small cell lung cancer (NSCLC) and pancreatic cancer.</p> <p>SciBX 7(26); doi:10.1038/scibx.2014.781 Published online July 10, 2014</p>	Patent and licensing status unavailable	<p>Izumchenko, E. <i>et al. Cancer Res.</i>; published online May 15, 2014; doi:10.1158/0008-5472.CAN-14-0110 Contact: David Sidransky, The Johns Hopkins University, Baltimore, Md. e-mail: dsidrans@jhmi.edu</p>